⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Wegovy (Semaglutide) | Accelerate Your Fibrosis Research

Home/Drugs/Wegovy

Wegovy

Semaglutide

Approved (MASH - FDA 2025)

Sponsor: Novo Nordisk

Indication: MASH / Obesity

Mechanism of Action

GLP-1 Receptor Agonist

Target: GLP-1

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT07096063

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

Org:Brigham and Women's Hospital

COMPLETED

Relevant Publications (PubMed)

No recent publications found for Semaglutide.

Validated Models

This drug has been validated in the following preclinical models:

NCT05891587

Semaglutide Therapy for Alcohol Reduction - Tulsa

Phase:PHASE2Org:Oklahoma State University Center for Health Sciences

COMPLETEDNCT04560998

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

Phase:PHASE3Org:Novo Nordisk A/S

COMPLETEDNCT02243098

Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects

Phase:PHASE1Org:Novo Nordisk A/S

NOT_YET_RECRUITINGNCT07030621

Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

Phase:PHASE3Org:RenJi Hospital

View all trials on ClinicalTrials.gov